Rachel P. Goodwin

Structural Interventional Cardiologist | SHD/IC @MidAmericaHeart // Married @egoodwi12 EP // Alum @UTK_cardiology & @UKYInternalMed //🫶🏼🫀

[Rachel P. Goodwin @DrRachelGoodwin]

Participated in 2 Live cases for #ACC24
🫀 Peripheral: CTO L-SFA (ADR)
🫀 Coronary: CTO PCI RCA (retrograde, guideliner facilitated X-CART via tortuous epicardial collaterals)
🫶🏼 learning from the best🌟 @MidAmericaHeart @JAG24851 @DanyJacob87 @mcbunte

[Oscar Mendiz @omendiz]

Great job Dimitri and all the colleagues from Brazil for the SURViV Trial showing that mitral ViV was superior to redo surgery at 1-year Follow-Up

[Muhammad Anis Haider @MAnisHaider]

🚨Built for shock → works in shock

Not for routine prophylactic use.

Hats off to all investigators—practice-changing evidence for better care👏🏼👏🏼👏🏼

[C. Michael Gibson MD @CMichaelGibson]

PRO-TAVI trial: Deferring PCI was non-inferior to routine PCI before TAVI for the 1-year composite of all-cause mortality, MI, stroke, and major bleeding, suggesting its appropriate role in selected CAD patients. #ACC26 View slides here: https://t.co/YhMHn8HumV

[The Lancet @TheLancet]

PCI before TAVI—necessary?

In patients with CAD, deferring PCI was noninferior to a PCI-first strategy at 1 year for the composite of death, MI, stroke, and major bleeding.

https://t.co/KwN2tauPyY #ACC26

[JACC Journals @JACCJournals]

In patients with symptomatic single-vessel chronic total occlusion, percutaneous coronary intervention for coronary chronic total occlusion (CTO PCI) improves angina beyond placebo.

Get the details in #JACC: https://t.co/yX0FDuSOjl #ACC26 #PCI #CTO @dr_skhan1

[Davide Capodanno @DFCapodanno]

Another micro-axial flow pump trial, this time in high-risk PCI—same leap of faith, same outcome. Result? No benefit. If anything, a signal in the wrong direction. We keep expanding “protected PCI” without proof it protects patients—only operators. When doing more starts to look like doing harm, it’s time to pause. #ACC26 https://t.co/zH2VQBCJS7

[The Lancet @TheLancet]

Clopidogrel vs aspirin after PCI:

10-year HOST-EXAM follow-up shows lower ischemic and bleeding events with clopidogrel—but no difference in mortality.

Read more: https://t.co/lJxVcoJxzW #ACC26

[Davide Capodanno @DFCapodanno]

Finally, a sham-controlled CTO PCI trial—and it delivers. ORBITA-CTO: small (n=50), but rigor where it matters—blinding, placebo control, symptom-level data. CTO PCI improves angina beyond placebo, with a clear reduction in episodes and more angina-free days. Not prognosis, not hard endpoints, but real symptom benefit—properly measured. #acc26
https://t.co/UgoJVoX87H

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

The placebo-controlled PCI debate returns this time with the 1st RCT blinded sham PCI trial for CTO 👏🏽👏🏽

#ORBITA-CTO evaluates PCI vs placebo in chronic total occlusions

➡️ Key results:
🎷CTO PCI ⤵️ angina frequency: immediate, sustained & consistent with OR=4.38 of improved angina symptoms & led to ~30 days angina free days

50 patients randomized, daily recording of angina episodes with app

#ACC26 #CTO #Cardiotwitter #LBCT @JACCJournals #orbitacto

[Aaysha Cader @aayshacader]

In the placebo-controlled ORBITA- CTO trial (n=50), presented today by @dr_skhan1 , PCI improves angina beyond placebo in symptomatic single-vessel CTO

Simpub: https://t.co/wH4m7zBaus

#ACC26 @ACCinTouch @DrKeeble @EssexCTC @rallamee @realarainmd @DrOzanDemir @esbrilakis

[Shariq Shamim @ShariqShamimMD]

Impella support for CHiP PCI RCT CHIP-BCIS3 at #ACC26 Very high syntax score! Much lower bleeding due to CT planning and preclosure. Win Ratio 0.85 but with CI crossing 1. Higher all cause death in Impella (statistically not significant). WOW.

[Amitabh Yaduvanshi MD, DM, FACC, FSCAI @IntervnCardio]

🚨 𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 from #ACC2026: Two major RCTs just challenged everything we thought about Impella pumps in cardiac care.

The results? Surprising.
The implications? Massive.

A thread on what every cardiologist needs to know 🧵👇

[Saint Luke's Mid America Heart Institute @MidAmericaHeart]

Happy to share that the @MidAmericaHeart team was the first in the region to perform transcatheter tricuspid valve replacement using the Edwards Evoque Valve. This device is commercially approved to treat TR and improve symptoms of heart failure. 

@saintlukeskc @akcmahi

[Rachel P. Goodwin @DrRachelGoodwin]

IC Graduation “Toast” & Fellow Farewell 6/20/24 🤍🥹🫀🫶🏼✨🌟@MidAmericaHeart @JAG24851 @noman_anas

[Rachel P. Goodwin @DrRachelGoodwin]

IC Fellowship Graduation 2024✨ Hands down the best year of training so far! Thankful for amazing @MidAmericaHeart attendings, outstanding mentor and our Teacher of the Year @JAG24851, program director Dr. Hart, co-fellow @noman_anas and my husband @egoodwi12 🤍

[EuroIntervention @EuroInterventio]

RENAL DENERVATION IN THE MANAGEMENT OF HYPERTENSION
This new State-of-the-Art:
✅ summarises the rationale for RDN,
✅ reviews the available evidence,
✅ provides recommendations for a safe procedure,
✅ discusses the role of RDN in current guidelines and clinical practice. #EAPCI #CardioTwitter @LucasLauder
https://t.co/rtzwOkyHaJ

[JessicaVKaczmarekMD @KaczmarekMD]

It’s totally in vogue to get your lipoprotein a Lp(a) level checked once in your life (value doesn’t change much after 5 years of age). Lp(a) is a marker of cardiovascular disease and calcific AS. @ACCinTouch had a booth to get yours! #prevention @AWaringCardio #lipids

[C. Michael Gibson MD @CMichaelGibson]

In the PREVENT trial, preventive PCI plus OMT resulted in a lower incidence of MACE vs. OMT alone in pts with non-flow-limiting vulnerable plaques

[Duk-Woo Park @dukwoo_park]

A long-waited PREVENT trial is now presented at LBCT-V #ACC2024
🇰🇷From the inception of trial to completion of trial took a decade.
✅1,606 pts with intracoronary imaging-detected “Vulnerable Plaque” randomized 1:1 to (1) Preventive PCI vs (2) OMT alone.
✅Prevent PCI significantly reduce primary composite endpoint (CV death, TV-MI, TVR, hospitalization for UA) at 2 yr. The effect of Preventive PCI was sustained up to 7 years.
✅First RCT shows that Preventive PCI is effective for non-flow limiting vulnerable atherosclerosis coronary plaque.
✅We believe that PREVENT would be one of the seminal investigations in the history of PCI.
@dukwoo_park @GreggWStone @JungMinAhn5 @DFCapodanno @djc795 @TheLancet
Further details:
https://t.co/R2NJ0dsdML

[Esther Kim @EstherSHKimMD]

Really important work presented by Dr Lori Tam on behalf of @iSCADregistry. n=1414 patients in 5 years is a testament to the power of collaboration in the science of rare/uncommon disease. @SCADalliance @providence @drmalissawood @katherinekleon